Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

Patients treated at the initial dose in an ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days

Conference Call Today at 8:30AM EST

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) in this first cohort of the study.

Patients in the first cohort received 200 mg ANA598 (n=8) or placebo (n=2), twice-daily (bid) for three days. At the end of the treatment period, the median viral load decline was 2.5 log10 (>99%), with a range of 1.4-3.4 log10, for the eight patients who received ANA598. Three patients who received ANA598 were genotype 1a and demonstrated a median viral load decline of 1.6 log10, while five patients who received ANA598 were genotype 1b and demonstrated a median viral load decline of 2.6 log10. All eight patients who received ANA598 demonstrated a rapid decline in viral load, and no patients demonstrated viral rebound while on study drug. In addition to the robust viral load decline, ANA598 was very well-tolerated and there were no serious adverse events in the first dose cohort, although conclusions regarding longer-term safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. Patients are currently being enrolled in the second cohort (400 mg bid) of the study. Anadys expects to report detailed data from multiple cohorts of the study at an upcoming medical conference.

"We are very pleased with the antiviral activity and safety of ANA598
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)... Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... treatments for cancer and its associated pain, today announced ... development of a small molecule inhibitor targeting the important ... protein has also been recognized as an important determinant ... as a dominant factor in most human cancers and ...
(Date:7/21/2014)... MARYVILLE, Ill. , July 21, 2014 /PRNewswire-iReach/ ... that Dr. Ryan Diederich has been ... on Membership and Advocacy for 2014-2015. This council ... member resources, services and benefits. The ... that represents and unifies its physician members as ...
Breaking Medicine Technology:Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4
... Dec. 21, 2011  VIVUS, Inc. (NASDAQ: VVUS ... retrospective study of medical claims data on oral ... utero .  The study, known as FORTRESS for ... mother-infant dyads exposed to topiramate either alone (monotherapy) ...
... Dec. 21, 2011 Despite the numerous medical advances ... the United States is still higher than most European ... the growing rate of pre-term births, researchers are committed ... Northwestern Medicine ® researchers are examining ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6Northwestern Researchers Trial New Device that May Support Improved Newborn Health 2Northwestern Researchers Trial New Device that May Support Improved Newborn Health 3Northwestern Researchers Trial New Device that May Support Improved Newborn Health 4
(Date:7/22/2014)... 2014 A new and technologically unique ... with results that are surprising even the most skeptical ... skin with radio frequency, ThermiTight has been dubbed “InjectableRF” ... the skin to “inject” heat to the tissues which ... single treatment solution for skin laxity produces results in ...
(Date:7/21/2014)... On Monday, September 22, 2014 Push to Walk will ... Solutions at The Knoll West Country Club, Knoll & Greenbank ... at 11 a.m. The price of $225 includes all ... $250 after September 7th. Non-golfers and guests are welcome ... dinner will include a special silent and live auction in ...
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
(Date:7/21/2014)... Center for Public Affairs Research has released the results ... what it means to be a quality health care ... the Robert Wood Johnson Foundation, sheds new light on ... care and doctors, as well as the information they ... survey produces new and actionable data during a crucial ...
Breaking Medicine News(10 mins):Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... of therapeutic agents that interferes with the ability of ... The results of the new study will be presented ... Meeting in San Francisco. , The cell-based study ... compounds are likely to be effective against breast cancers ...
... scientists work collaboratively, barriers of religion and ethnicity ... science to improve the lives of citizens worldwide. ... Gluck, professor of neuroscience at Rutgers University in ... after successfully organizing an international conference co-hosted by ...
... 16 Pittsburgh-based Foundation,Radiology Group (FRG) and Cherry ... which will make FRG the exclusive provider of,diagnostic ... Kishor E. Joshi, M.D., president of Cherry Tree ... Foundation Radiology Group. We expect,this partnership will enhance ...
... Association, a,regional non-profit established to foster relationships and ... announced today,the election of five new officers and ... New officers who were elected to serve a ... president, Aon Consulting; Past President - Thomas,Hoffman, partner, ...
... studies indicate that oral use of RU-486,s companion drug misoprostol ... , The off-label use of a drug given with RU-486 ... of rare, fatal infections seen in women taking the drugs ... , The drug misoprostol is FDA-approved to be taken ...
... & Lymphoma Society,s Light The Night(R) Walk Offers Relief at ... the ... prices may be,putting the brakes on Americans, summer travel plans, but The ... cards,and a chance to win an all-expense paid vacation., Light The ...
Cached Medicine News:Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:US-Israeli-Palestinian collaboration to advance Alzheimer's disease research 2Health News:Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services 2Health News:SouthWest Benefits Association Elects New Board of Directors 2Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3Health News:Get Free Gas and Help Save a Life 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: